Baldenkov G N, Akopov S E, Ryong L H, Orekhov A N
Institute of Experimental Cardiology, USSR Cardiology Research Center, Moscow.
Biomed Biochim Acta. 1988;47(10-11):S324-7.
We investigated the effects of stable analogues of prostacyclin (carbacyclin) and thromboxane A2 (U46619) and various calcium antagonists on atherosclerotic cellular indices, intracellular cholesterol content and [3H]thymidine incorporation. Primary culture of human subendothelial cells derived from atherosclerotic plaques of aorta was used. Carbacyclin reduced cholesterol accumulation and cell proliferation. U46619 in opposite to carbacyclin stimulated this processes. In general, carbacyclin exerted a direct antiatherosclerotic and U46619 - atherogenic action in culture. Calcium antagonists: dihydropyridines, verapamil derivatives and diltiazem demonstrated antiatherosclerotic properties themselves and potentiated carbacyclin effect but restricted atherogenicity of U46619.
我们研究了前列环素(卡前列素)和血栓素A2(U46619)的稳定类似物以及各种钙拮抗剂对动脉粥样硬化细胞指标、细胞内胆固醇含量和[3H]胸腺嘧啶核苷掺入的影响。采用源自主动脉粥样硬化斑块的人内皮下细胞原代培养。卡前列素减少胆固醇积累和细胞增殖。与卡前列素相反,U46619刺激这些过程。总体而言,卡前列素在培养物中发挥直接抗动脉粥样硬化作用,而U46619具有致动脉粥样硬化作用。钙拮抗剂:二氢吡啶类、维拉帕米衍生物和地尔硫䓬本身具有抗动脉粥样硬化特性,并增强了卡前列素的作用,但限制了U46619的致动脉粥样硬化性。